Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (1869)	8/24/2007 11:23:31 PM
From: Jibacoa	Respond to of 3722

Yes,the Sep issue of BW mentions that ARNA is expected to announce the 6 months safety review of lorcaserin, which is on a PIII for treatment of obesity. Some analysts say that so far the data have been positive & the drug could be a multi-billion$$ drug & have a 12 month "target" for the stock around $25.(Lorcaserin isn't expected to be selling until 2010.)YHOO's "target" for ARNA is around $20.<g> businessweek.com The stock was able to close above the initial resistance of $!3 and the next resistance is now at $13.75 The short position was around 9x its DAV, so there could be some short covering next week.<g> bigcharts.marketwatch.com Bernard